Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma

Oncology Reports

Volumn 23, Issue 4, 2010, Pages 957-963

  Kondo, Norio ^a   Tsukuda, Mamoru ^a   Ishiguro, Yukari ^a   Kimura, Machiko ^a   Fujita, Kyoko ^a   Sakakibara, Atsuko ^a   Takahashi, Hideaki ^a   Toth, Gabor ^a   Matsuda, Hideki ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; EGFR; Head and neck squamous cell carcinoma; HER 2; Lapatinib; Paclitaxel

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IC 50; MICROVASCULARIZATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; HEAD AND NECK NEOPLASMS; HUMANS; IN SITU NICK-END LABELING; INHIBITORY CONCENTRATION 50; MICE; PACLITAXEL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949445285     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000720     Document Type: Article

References (46)

1. Eisbruch A, Blick M, Lee JS, Sacks PG and Gutterman J: Analysis of the epidermal growth factor receptor gene in fresh human head and neck tumors. Cancer Res 47: 3603-3605, 1987.
2. Santini J, Formento JL, Francoual M, et al: Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13: 132-139, 1991.
3. Dassonville O, Formento JL, Francoual M, et al: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11: 1873-1878, 1993.
4. Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000.
5. Khademi B, Shirazi FM, Vasei M, et al: The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors. Cancer Lett 184: 223-230, 2002.
6. Pornchai OC, Rhys-Evans PH, Modjtahedi H and Eccles SA: The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol 38: 627-640, 2002.
7. Alaoui-Jamali MA, Paterson J, Al Moustafa AE and Yen L: The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem Cell Biol 75: 315-325, 1997.
8. Rogers SJ, Harrington KJ, Rhys-Evans P, Pornchai OC and Eccles SA: Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 24: 47-69, 2005.
9. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356, 2002.
10. Shewchuk L, Hassell A, Wisely B, et al: Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J Med Chem 43: 133-138, 2000.
11. Agulnik M, Cohen EW, Cohen RB, et al: Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25: 3978-3984, 2007.
12. Harrington KJ, El-Hariry IA, Holford CS, et al: Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 27: 1100-1107, 2009.
13. Formento P, Hannoun-Levi JM, Fischel JL, Magne N, Etienne-Grimaldi MC and Milano G: Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab. Eur J Cancer 40: 2837-2844, 2004.
14. Warburton C, Dragowska WH, Gelmon K, et al: Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 10: 2512-2524, 2004.
15. Nakamura H, Takamori S, Fujii T, et al: Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. Cancer Lett 230: 33-46, 2005.
16. Fukutome M, Maebayashi K, Nasu S, Seki K and Mitsuhashi N: Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ('Iressa') and trastuzumab ('Herceptin'). Int J Radiat Oncol Biol Phys 66: 528-536, 2006.
17. Kondo N, Ishiguro Y, Kimura M, et al: Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. Oncol Rep 20: 373-378, 2008.
18. Grandis JR and Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53: 3579-3584, 1993.
19. Rubin Grandis J, Melhem MF, Gooding WE, et al: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90: 824-832, 1998.
20. Huang SM, Li J, Armstrong EA and Harari PM: Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62: 4300-4306, 2002.
21. Bei R, Budillon A, Masuelli L, et al: Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol 204: 317-325, 2004.
22. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
23. Zhau HE, Zhang X, von Eschenbach AC, et al: Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog 3: 254-257, 1990.
24. Kapitanovic S, Radosevic S, Kapitanovic M, et al: The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112: 1103-1113, 1997.
25. Erjala K, Sundvall M, Junttila TT, et al: Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 12: 4103-4111, 2006.
26. Graus-Porta D, Beerli RR, Daly JM and Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647-1655, 1997.
27. Pinkas-Kramarski R, Soussan L, Waterman H, et al: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15: 2452-2467, 1996.
28. Karunagaran D, Tzahar E, Beerli RR, et al: ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15: 254-264, 1996.
29. Taguchi T, Tsukuda M, Imagawa-Ishiguro Y, Kato Y and Sano D: Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. Oncol Rep 19: 65-71, 2008.
30. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, et al: Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 42: 109-111, 2006.
31. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005.
32. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
33. Cappuzzo F, Magrini E, Ceresoli GL, et al: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96: 1133-1141, 2004.
34. Balak MN, Gong Y, Riely GJ, et al: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12: 6494-6501, 2006.
35. Kosaka T, Yatabe Y, Endoh H, et al: Analysis of epidermal growth factor receptor gene mutation in patients with nonsmall cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764-5769, 2006.
36. Cappuzzo F, Ligorio C, Janne PA, et al: Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 25: 2248-2255, 2007.
37. Sasaki H, Endo K, Takada M, et al: EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 58: 324-328, 2007.
38. Stephens P, Hunter C, Bignell G, et al: Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431: 525-526, 2004.
39. Shimamura T, Ji H, Minami Y, et al: Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV-G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 66: 6487-6491, 2006.
40. Konecny GE, Pegram MD, Venkatesan N, et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630-1639, 2006.
41. Zhou Y, Li S, Hu YP, et al: Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res 66: 404-411, 2006.
42. Di Leo A, Gomez HL, Aziz Z, et al: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26: 5544-5552, 2008.
43. Rocha-Lima CM, Soares HP, Raez LE and Singal R: EGFR targeting of solid tumors. Cancer Control 14: 295-304, 2007.
44. Fox WD, Higgins B, Maiese KM, et al: Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 8: 3226-3231, 2002.
45. Sweeney CJ, Miller KD, Sissons SE, et al: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61: 3369-3372, 2001.
46. Belotti D, Vergani V, Drudis T, et al: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843-1849, 1996.